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RETROSPECTIVE REVIEW OF THE USE OF PALIFERMIN TO PREVENT
MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
PATIENTS CONDITIONED WITH HIGH-DOSE CHEMOTHERAPY AND
TOTAL BODY IRRADIATION
Kennedy, D., Gigue`re, P., Corman, C., Hopkins, H. The OttawaHospital,
Ottawa, ON, Canada
Rationale: Mucositis is caused by chemotherapy and radiation and
is characterized by pain, erythema, and ulceration of the oral
mucosa. Palifermin is a keratinocyte growth factor approved for
the prevention of mucositis. The primary objective of this study
was to compare the proportion, duration, and severity of mucositis
in bone marrow transplant patients pre- and post-palifermin
treatment.
Methods: Data were collected retrospectively by a chart review on
patients who received high-dose chemotherapy and total body irra-
diation from January 2004 to February 2009 at The Ottawa Hospi-
tal. Results were analyzed before and after the introduction of
palifermin in August 2006. The severity of mucositis was assessed us-
ing the Bearman scale.
Results: Data were collected from 75 patient charts; 34 of which
received palifermin. The proportion of patients experiencing mu-
cositis was 97.6% for those who did not receive palifermin and
79.4% for those who received palifermin (p5 0.02). Bearman
scale grade$ 2 mucositis was experienced by 92.7% of patients
without palifermin compared to 47.1% with palifermin
(p\0.001). Palifermin reduced the median duration of mucositis
by 4.0 days (p5 0.009).
Conclusion: Palifermin reduced the proportion, severity, and dura-
tion of mucositis in this patient population.438
ELECTRONICAUTOMATIONOFTRANSPLANTCONDITIONINGPROTOCOLS
IN A PEDIATRIC BLOOD AND MARROW TRANSPLANT SERVICE
Wright, F.A.1, Trickett, A.E.2,3, O’Brien, T.A.1 1Centre for Children’s
Cancer and Blood Disorders Sydney Children’s Hospital, Randwick,
NSW, Australia; 2New South Wales Health, Sydney, NSW, Australia;
3University of New South Wales, Sydney, NSW, Australia
Currently there is no commercially available electronic automated
system for the prescribing of conditioning regimens for hematopoi-
etic progenitor cell transplants (HPC). To address this, with the aim
of improving patient safety and reducing prescriber errors, the BMT
Network NSW and the transplant program at Sydney Children’s
Hospital collaborated to develop electronic templates for 15 condi-
tioning regimens.
The Transplant Pharmacist and BMT Network Quality Man-
ager utilized Excel software to generate templates based on cur-
rent approved protocols which contain dropdown lists and
locked formulas. Drug doses are automatically calculated and
incorporate dose rounding according to the patient’s height,
weight and/or age. Donor and recipient transplant characteris-
tics, including HPC cell source and processing, and infectious
disease screening, automatically determine the majority of pro-
phylactic and supportive care. Each template was independently
validated by the Transplant Director to ensure that all formula
function correctly. Templates were then authorised, document
controlled and given a unique document identifier and version
number. Each template is password protected, locked and can-
not be changed without authorisation from the Transplant
Director.
When required for use, the appropriate conditioning regimen
template is selected and patient and donor parameters entered.
Non-automated supportive care (for example blood-product support
and choice of antifungal prophylaxis) can be selected from drop
down boxes. Once complete, the protocol is converted to Acrobat
pdf format, checked and signed by the Transplant Director and
Pharmacist then distributed. The signatures are password protected
and e-stamped with the time and date. No protocol once converted
to Acrobat can be changed.
Previously the preparation of a conditioning protocol was
a lengthy process with manual data collection and entry into
a Word document with multiple opportunities for prescriber er-ror. The development of electronic automated templates has im-
proved efficiency, reduced pharmacy and physician time
dedicated to this task, and in addition has reduced prescriber er-
ror and improved patient safety. This system could be easily
modified to incorporate site-specific rules at other transplant
centres.439
PLERIXA FOR DOSING AND ADMINISTRATION IN A PATIENT WITH
DIALYSIS DEPENDENT RENAL FAILURE
Gregory, K.M.1, Rao, K.V.1, Armistead, P.M.2,3, Shea, T.C.2,3 1Univer-
sity of North Carolina Hospitals, Chapel Hill, NC; 2University of North
Carolina Hospitals, Chapel Hill, NC; 3University of North Carolina,
Chapel Hill, NC
Background: Plerixafor, a CXCR4 antagonist, is approved for stem
cell mobilization for patients undergoing autologous stem cell trans-
plantation, and is useful in the mobilization of patients who have
failed mobilization previously. The approved dosing recommends
a dose adjustment for mild to moderate renal impairment, but no
specific details on dosing in dialysis patients.
Objective:To describe the first reported U.S. experience with use of
plerixafor in dialysis dependent renal failure.
Methods: A 38 year old patient with ISS stage 3 multiple myeloma
was evaluated in our outpatient stem cell transplantation clinic.
The patient had developed renal failure secondary to his myeloma
with a baseline glomerular filtration rate of less than 20 ml/min.
Standard filgrastim-based mobilization was unsuccessful with the
patient’s maximum pre-pheresis CD34+5 5.6 cells/mL. Based on
limited data from Europe, and evaluation of the pharmacokinetic
properties of plerixafor, the patient was treated with G-CSF
(10ug/kg/day) for 4 days and a post-dialysis dose of plerixafor at
a dose of 160 mcg/kg on the evening of day 4, followed by stem
cell collection 12 hours later on Day 5. Dialysis was held during
the attempted mobilization, to avoid removal of plerixafor by ultra-
filtration.
Results: Adequate stem cell yield was obtained with a single dose
of plerixafor in this patient. The morning after initial plerixafor
dosing, the patient’s pre-pheresis CD34+5 125.62 cells/mL.
The patient underwent successful stem cell collection with a yield
of 5.33106 CD34+ cells/kg after his first apheresis session.
Discussion: Based upon our experience with plerixafor in a dialysis-
dependent patient, we are instituting a policy to dose plerixafor at
typical renal adjustment doses, with dialysis sessions being scheduled
prior to plerixafor administration, and repeated, as clinically neces-
sary, after apheresis and prior to the subsequent plerixafor dose. If
clinically feasible, we would recommend avoiding dialysis during
the days required to collect stem cells, although in our single patient
experience, this was not necessary.440
CONTINUOUS INFUSION (CI) CYCLOSPORINE (CSA): ASSESSMENT OF
DOSING IN PEDIATRIC AND ADOLESCENT PATIENTS (PTS) WITH
WEIGHT. 50 KG DURING HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT)
Shinkle, M.1, Duerst, R.1,2 1Children’s Memorial Hospital, Chicago, IL;
2Northwestern University, Feinberg School of Medicine, Chicago, IL
Continuous Infusion CsA (5 mg/kg/day) is used for GVHD pro-
phylaxis at Children’s Memorial Hospital (CMH) following full in-
tensity conditioning allogeneic HSCT. Toxicities from CsA are
common and require careful monitoring. A drug utilization evalu-
ation was conducted assessing CI CsA to determine the following
parameters: dose adjustments, drug levels, and toxicities. This ret-
rospective analysis for the drug evaluation report was generated
from the electronic medication entry system (EPIC). Medication
codes for intravenous CsA were used to obtain data on those pts
who received CI CsA. Patient weight, initial CI CsA dose, time
CsA was initiated, measured levels of CsA, and time and amount
of dosage changes were analyzed. From June 2007 through
Poster Session II S319February 2009, 33 pts received CI CsA during their allogeneic
HSCT. Thirteen of these pts weighed$ 50 kg: 9 were males, the
median age was 16 years (11-18 years) and the mean weight was
66.3 kg (51.7 – 88 kg). Seven of 13 pts received dosa-
ges. 250 mg/day based on weight (6 of whom received 5 mg/kg/
day and 1 received  4 mg/kg/day (300 mg/day). Six pts received
dosages# 250 mg (5 of whom received 250 mg/day and 1 received
200 mg/day). After initial steady state, the median CsA level was
436 ng/ml (220-806, Mass-spectrometry). Toxicities that required
dose adjustment include: Hypertension (n5 5) Hyperbilirubinemia
(n5 3), increase in BUN/Cr (n5 1). 71% of pts$ 50 kg who re-
ceived weight based doses. 250 mg/day required a dose reduction
by the fifth day of therapy while none of the pts$ 50 kg receiving
doses# 250 mg/day needed dose adjustments (p5 0.02, Fisher’s
Exact Test). Two pts who received .250 mg/day dosage and did
not have a dose reduction in the first five days of therapy required
a dose reduction within 10 days of initiation of CsA due to toxicity.
No patients receiving the 250 mg maximum dose required an in-
crease above 250 mg in the first 5 days of therapy or dose adjust-
ment due to toxicity. This data supports the implementation of
a 250 mg/day maximum dosage of CI CsA for patients who
weigh$ 50 kg.Multivariable Logistic Regression Model for acute GVHD
Outcome
Variable OR 95% CI P
MTX vs. Siro 4.47 1.33-15 0.015
Age 0.894 0.95-1.04 NS
Female vs. Male 0.258 0.2-1.53 NS
MUD vs. MRD 0.842 0.36-3.49 NS
Acute Leukemia vs. Other 0.212 0.64-6.99 NS
Donor CMV positive 0.724 0.29-2.36 NS
Recipient CMV positive 0.008 1.5-14.4 0.008
PBSC vs. BM 0.159 0.71-7.85 NS
ATG 0.568 0.11-3.25 NS441
POLYOMA VIRUS IS THE PRINCIPAL CAUSE OF CYSTITIS FOLLOWING
ALEMTUZUMAB-BASED ALLOGENEIC STEM CELL TRANSPLANTATION
Khan, T.1, Richard, K.2, Broadwater, G.3, Hemphill, S.E.2, Lassiter, M.2,
Horwitz, M.E.4 1Duke University Medical Center, Durham, NC; 2Duke
University Medical Center, Durham, NC; 3Duke University Medical
Center, Durham, NC; 4Duke University School of Medicine, Durham,
NC
Polyoma virus reactivation and related cystitis in patients under-
going allogeneic hematopoietic stem cell transplant (alloHSCT) is
associated with significant morbidity. We conducted a retrospec-
tive review of 604 patients undergoing alloHSCT at Duke Univer-
sity Medical Center between Jan 1995 to Dec 2008. Polyoma virus
screening was performed on urine samples using electron micros-
copy (EM). EM screening was performed on 192 (32%) patients
with cystitis symptoms (dysuria, urgency, hesitancy, hemorrhage,
frequency). EM screened patients were evaluated for incidence
of polyoma infection, duration of symptoms, hemorrhagic cystitis,
and possible risk factors. Logistic regression modeling was used to
predict EM positivity in the 192 patients with symptomatic cysti-
tis. Pearson’s Chi-Square test was used to compare differences in
proportions. Of 192 patients screened, 96 (50%) tested positive
for polyoma virus. The median time to EM positivity was 1.38
months (n5 88). The median duration of symptoms in the EM
positive group was 1 month (range 15 days – 1 year), compared
to 15 days (range 15 days – 3 months) in the EM negative group.
Patients with symptomatic cystitis undergoing an alemtuzumab-
containing non-myeloablative transplantation (NMAT) had
a higher incidence of polyoma infection compared to standard
myeloablative alloHSCT (62% vs. 32%, Chi sq p\0.001). In
a subgroup analysis of NMAT patients, comparing regimen inten-
sity (Fludarabine/Cyclophosphamide 2 g/m2 vs. Fludarabine/Mel-
phalan 140 mg/m2 or Busulfan 260 mg/m2), no difference in the
incidence of polyoma infection was detected (67% vs 74%, Chi-
sq p5 0.497). This indicates that T-cell depletion has a greater
impact than regimen intensity on the development of polyoma in-
fection. Patients who received transplantation from a haploidenti-
cal donor were at greatest risk for developing polyoma infection
(Chi-sq p5 0.041). We found no difference in polyoma infection
rates based on the severity of graft vs. host disease. Ciprofloxacin
use did not attenuate the incidence of polyoma infection. A mul-
tivariate regression analysis identified alemtuzumab-containing
NMAT, haploidentical donor, and concurrent CMV infection as
risk factors for the development of polyoma infection. We con-
clude that polyoma virus was the predominant source of cystitis
in patient undergoing an alemtuzumab-containing NMAT. In
contrast to other published reports, regimen intensity is not
a major factor.442
SIROLIMUS COMPARED TO METHOTREXATE BASED IMMUNOSUPPRES-
SION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN AL-
LOGENEIC STEM CELL TRANSPLANTATION: A SINGLE INSTITUTION
EXPERIENCE
Kiel, P.J.1, Rosenbeck, L.L.1, Kalsekar, I.2, Baute, J.1, Abdelqader, S.1,
Sullivan, C.K.1, Schwartz, J.1, Srivastava, S.1, Abonour, R.1,
Robertson, M.J.1, Nelson, R.P.1, Fausel, C.A.1, Farag, S.S.1 1 IU Simon
Cancer Center, Indianapolis, IN; 2Butler University, Indianapolis, IN
Methotrexate (MTX) is a standard agent used in combination
with calcineurin inhibitors for GvHD prophylaxis in patients un-
dergoing an allogeneic hematopoeitic stem cell transplant
(HCT). We compared the incidence of acute GvHD following
allogeneic transplantation using the combination of sirolimus
(siro) and tacrolimus (tacro) to MTX plus either tacro or cyclo-
sporine.
Between January 1, 2005 and April 30, 2009, 106 consecutive
patients who received allogeneic bone marrow or peripheral blood
stem cell (PBSC) transplantation using a myeloablative regimen
for hematological malignancies were evaluated. Patients were
included if they were. 18 years old, and matched at least at HLA-
A, -B, and DRB1 by high-resolution typing. Patients receiving
reduced-intensity or cord blood transplantation were excluded.
The primary endpoint was the incidence and severity of acute
GvHD. Secondary endpoints included chronic GvHD, incidence
of venoocclusive disease (VOD), thrombotic microangiopathy
(TMA), interstitial pneumonitis (IP).
The median (range) age for the siro (n5 59) and MTX (n5 47)
groups were 44 (21-59) and 39 years (20-57), respectively. Of pa-
tients receiving MTX, 33 (70%) also received cyclosporine and 14
(30%) tacro. Thirty-four (57%) patients in the siro group and 19
(40%) in the MTX group received stem cells from matched unre-
lated donors (MUD). Forty-seven percent of MUD patients received
antithymocyte globulin (ATG) with siro/tacro.
The incidence of grade II-IV acute GvHD before day +100 was
18.6% in patients receiving siro/tacro, compared to 48.9% receiving
MTX (p5 0.001). The incidence of grade III-IV acute GVHD was
5% and 17% (p5 0.045) for the siro and MTX group, respectively.
The incidence of chronic GvHD was not significantly different be-
tween siro or MTX (32% vs. 38%, p5 0.5). Similarly, there was
no significant difference in the incidence of TMA or IP. However,
VOD occurred in 20% (attributable mortality in 8/12 patients)
who received siro compared to 4% in those receiving MTX (OR
0.103, 95% CI 0.10-1.093, p5 0.059).
This retrospective analysis demonstrated that the combination of
siro and tacro provided more effective acute GvHD prophylaxis
compared to MTX-based immunosupression. Siro was also associ-
ated with an increased incidence of VOD.TRANSPLANT NURSING: ADMINISTRATION
443
ASSESSING PATIENT SATISFACTION IN AN OUTPATIENT APHERESIS SET-
TING
Merkel, D., Hirner, A., Gaillard, K., Torry, M., DeJarnette, S.,
Trieu, K., Lenz, K., Abhyankar, S. University of Kansas Hospital, Kansas
City, KS
